Follow-up study for high-risk eye melanoma after treatment
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Have uveal melanoma considered high risk for spread/relapse (based on tumor features or chromosome changes)
- Finish treatment for the main eye tumor within the last 2 months
- Be able to attend the study visits and have required blood tests
- Have signed informed consent (or your legal representative can sign)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at past medical records of people diagnosed with uveal melanoma. It helps researchers learn about the typical course of the disease by analyzing what already happened in care.
This Phase 3 study tests whether taking melatonin after treatment for uveal melanoma can reduce the chance that the cancer returns or spreads to other parts of the body. It is aimed at people with higher-risk eye melanoma features.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
This study checks whether blood “biomarkers” (measurable signs in serum) can help diagnose metastatic uveal melanoma. If you have uveal melanoma, the study may look at how useful these blood tests are for spotting spread to other parts of the body.
This study looks for new inherited genes linked to uveal melanoma (an eye cancer). If you have this cancer and don't already have a known genetic cause, you may be able to help find new genes that affect cancer risk.
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.